Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daclizumab + tacrolimus
- Development stage
- Discontinued
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination immunosuppressive therapy used primarily to prevent organ transplant rejection, particularly in kidney transplantation. This regimen combines daclizumab, a humanized monoclonal antibody targeting CD25 (IL-2 receptor alpha chain), with tacrolimus, a calcineurin inhibitor. The combination provides complementary mechanisms of action to prevent T-cell activation and proliferation, thereby reducing the risk of acute rejection in transplant recipients.
02
Targets
CN (Calcineurin)FKBP1AIL2RA (Interleukin-2 receptor alpha subunit)
Beyond the preview
Go deeper on daclizumab + tacrolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daclizumab + tacrolimus.